AbbVie Presents New Upadacitinib Data In Atopic Dermatitis

  • AbbVie Inc ABBV announced new analyses from the Phase 3 Rinvoq (upadacitinib) atopic dermatitis clinical trial program.
  • Data were presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress.
  • One analysis showed a greater proportion of patients treated with Rinvoq (15 mg or 30 mg; once daily) with or without topical corticosteroids achieved 75% improvement in the Eczema Area Severity Index (EASI 75) at week 16 compared to placebo regardless of age, sex, race, weight, disease severity and previous exposure to systemic therapy.
  • An additional analysis showed that more patients treated with Rinvoq 30 mg achieved EASI 75 at week 16 than dupilumab when measured in four body regions.
  • No new safety risks were observed.
  • Price Action: ABBV stock is down 0.03% at $108.81 during the market session on the last check Thursday.
  • Editor's Note: The story has been updated with additional details.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralatopic dermatitisBriefsPhase 3
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!